Streetbeat News

Products Services

ADAG

MRK

Adagene Inc. presented new data at the ESMO Congress on their ADG126 therapy in combination with Merck's KEYTRUDA for metastatic colorectal cancer. The data shows significant clinical benefits, supporting further development.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:03 am

VCYT

Veracyte's Decipher Prostate Test has shown promising results in predicting chemotherapy benefits for metastatic prostate cancer patients, as presented at ESMO 2024. This data supports Veracyte's plan to expand the test's use to metastatic disease patients.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:02 am

JNJ

Johnson & Johnson presented new data at the ESMO Congress showing promising results for RYBREVANT in treating metastatic colorectal cancer. The study demonstrated rapid and durable antitumor activity in patients who have not previously received anti-EGFR therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:01 am

JNJ

Johnson & Johnson announced new data from the Phase 2b SunRISe-1 study, highlighting the safety and efficacy of TAR-200 for treating BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. The findings were presented at the ESMO 2024 Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:59 am

BMY

Bristol Myers Squibb's Checkmate-067 trial shows a 10-year follow-up with Opdivo + Yervoy in advanced melanoma, indicating a significant long-term survival benefit. Over 40% of patients were alive after ten years, compared to a 25% survival rate a decade ago.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:58 am

JNJ

Johnson & Johnson's Phase 2 trial of TAR-200 plus cetrelimab shows promising results in bladder cancer treatment, nearly doubling the response rate compared to cetrelimab alone.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:57 am

EXAS

Exact Sciences Corp. presented promising data for its blood-based colorectal cancer screening test at the ESMO Congress, showing high sensitivity and specificity. This development could enhance cancer screening options.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:53 am

REPL

Replimune announced positive primary analysis results from the IGNYTE clinical trial of RP1 in combination with Nivolumab for anti-PD1 resistant melanoma at the 2024 ESMO Congress. The data shows clinically meaningful activity across all subgroups, including those with prior anti-PD1 and anti-CTLA-4 treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:46 am

ESALF

MRK

Merck and Eisai's Phase 3 LEAP-012 trial shows that the combination of KEYTRUDA and LENVIMA with TACE reduces the risk of disease progression or death by 34% in advanced liver cancer patients compared to TACE alone. These results were presented at the European Society for Medical Oncology Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:36 am

MRK

Merck's KEYTRUDA, combined with chemoradiotherapy, reduces mortality risk by 33% in high-risk cervical cancer patients, marking a significant advancement in treatment. The KEYNOTE-A18 study is the first Phase 3 trial to show improved survival rates with this combination, with results presented at the ESMO Congress 2024 and published in The Lancet.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:31 am